ArticleIrish journal of medical science2026
The effect of PARP and PLK1 dual inhibition on the expression of important protein signaling pathways, DNA damage, and molecular docking scores against MCF-7 and MDA-MB-231 breast cancer cell lines.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resveratrol potentiates chemotherapeutic efficacy of olaparib in MCF7 human breast cancer cells by inducing apoptosis.Irish journal of medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSmall molecule PARP inhibitors, such as olaparib, have been developed as part of personalized cancer treatment strategies.
aimThis study investigated the synthetic lethality between the PARP enzyme in breast cancer cell lines.
methodsThe anti-cancer effects of combining the PARP inhibitor olaparib with the small molecule PLK1 inhibitor BI-2536 on MCF-7 and MDA-MB-231 breast cancer cells were assessed through in vitro cell viability (MTT) and clonogenic cytotoxicity analyses. The impact of olaparib and BI-2536 treatment on cell cycle and DNA damage response proteins was analyzed using Western blotting. BRCA2 expression was silenced using RNA interference technology, and the manipulation of BRCA2 gene expression in MCF-7 breast cancer cells was confirmed by Western blotting. Cell viability and colony survival were evaluated in BRCA2-effective and BRCA2-defective MCF-7 cells. Additionally, molecular docking analyses provided insights into the functioning of protein signaling pathways.
resultsOur results indicate that the combined treatment with olaparib and BI-2536 significantly reduces the viability of MCF-7 and MDA-MB-231 breast cancer cells and inhibits their colony formation ability. This combination therapy demonstrated a synergistic cytotoxic effect, causing potentiated DNA damage induction in these breast cancer cells compared to individual treatments.
conclusionsThe increased expression of PLK1, p53, p21, γH2AX, Nrf-2, cyclin E, A, and B1, along with the decreased expression of HER-2, NF-κB, and cyclin D1 in breast cancer cells, suggests that PLK1 inhibition can enhance the efficacy of PARP inhibitors.
Indexed as
Identifiers
41233610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.